US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Articles published by NICOX SA

News headline image
Nicox Reports First Half 2026 Financial Results
From NICOX SA
Via GlobeNewswire
News headline image
Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces NCX 470 NDA in China Accepted for Review
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Extension of Cash Runway
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension
From NICOX SA
Via GlobeNewswire
News headline image
Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment
From NICOX SA
Via GlobeNewswire
News headline image
Reminder: Nicox June 2024 Warrants will expire June 19, 2026
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Provides Full Year 2025 Financial Results and Corporate Update
From NICOX SA
Via GlobeNewswire
News headline image
Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470
From NICOX SA
Via GlobeNewswire
News headline image
Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470
From NICOX SA
Via GlobeNewswire
News headline image
Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Provides First Half 2025 Financial Results
From NICOX SA
Via GlobeNewswire
News headline image
Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Shareholder Q&A Webpage Available
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients
From NICOX SA
Via GlobeNewswire
News headline image
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
From NICOX SA
Via GlobeNewswire
News headline image
Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Provides Full Year 2024 Financial Results
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update
From NICOX SA
Via GlobeNewswire